AIM-listed cell engineering platform MaxCyte files for a $100 million US IPO

MaxCyte, which provides cell engineering devices and services, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company is currently listed on London’s AIM (MXCT).

MaxCyte’s Flow Electroporation technology facilitates the complex engineRead More